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ABSTRACT
Background. Reoperations occur frequently after initial
lumpectomy for breast cancer. The authors hypothesized
that the receipt of neoadjuvant chemotherapy (NAC) is
associated with fewer reoperations.
Methods. The association between timing of chemother-
apy and reoperation rates (ROR) after lumpectomy was
investigated for patients with stages 1–3 breast cancer in
the National Cancer Database (NCDB) from 2010 to 2013
by multivariable logistic regression modeling. Then
propensity score-matching was performed.
Results. The unadjusted ROR for 71,627 stages 1–3
patients was 11.4% for those who had NAC compared with
20.3% for those who had postoperative chemotherapy (p\
0.001) (odds ratio [OR] 0.53; 95% confidence interval [CI]
0.49–0.57; p\ 0.001). The ORs for the reoperations per-
formed for patients with stages 1, 2, and 3 cancers who
received NAC were respectively 0.65 (95% CI 0.56–0.75),
0.50 (95% CI 0.45–0.56), and 0.27 (95% CI 0.19–0.38)
The p values for all were lower than 0.001.
Conclusion. For a population of patients receiving
chemotherapy, the receipt of chemotherapy before instead
of after surgery was associated with fewer reoperations
after initial lumpectomy for breast cancer.
More than one in five patients treated with initial
lumpectomy for breast cancer need another operation for
perceived residual disease.1–4 In addition, there is strong
evidence for marked variability of reoperation rates
(RORs) among both individual surgeons and individual
institutions.1–3 Consequently, exploration of new methods
of care is needed to limit reoperations.5 This study aimed to
investigate whether the timing of chemotherapy is associ-
ated with a lower ROR in patient populations for whom
this treatment is appropriate.
Neoadjuvant chemotherapy (NAC) reduces the cancer
burden before operation for many patients, offering the
patient a better chance of successful breast conservation
rather than mastectomy.6 The number of patients with
newly diagnosed breast cancer who receive NAC is
increasing, but it still comprised less than 17% of all
patients undergoing operations recently reported in the
National Cancer Database (NCDB).6 For a population of
patients receiving chemotherapy, we hypothesized that
receipt of NAC is associated with fewer reoperations after
lumpectomy. We used the NCDB to test this hypothesis.
METHODS
The NCDB contains de-identified, Health Insurance
Portability and Accountability Act (HIPAA)-compliant
participant user files. All patient identifiers are removed.
Thus, institutional review board approval is not required.
‘‘The NCDB is a joint project of the American College of
Surgeons Commission on Cancer and the American Cancer
Society. The hospitals participating in the NCDB are the
source of the de-identified data used herein; they have not
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verified and are not responsible for the statistical validity of
the data analysis or the conclusions derived by the
authors.’’7,8
Study Population
The inclusion criteria specified female patients older
than 18 years receiving chemotherapy for clinical stages
1–3 invasive breast cancer who underwent initial lumpec-
tomy during the years 2010 to 2013. Patients with non-
primary breast cancer histologic codes, diagnosis by exci-
sional rather than needle biopsy, missing values for
reoperations, missing days from diagnosis to the first sur-
gical procedure or a definitive surgical procedure, or
missing predictor variables (chemotherapy timing) were
excluded from the study. Patients coded as having 0 days
from diagnosis to the first surgical procedure also were
excluded. Patients who had missing values for confounding
variables were treated as a separate category (unknown). A
patient cohort identical to the aforementioned patients
except for age restricted to older than 70 years also was
used in separate modeling.
Primary Outcome
The primary outcome variable was ROR within 60 days
after the initial lumpectomy for invasive breast cancer. A
reoperation could be either a lumpectomy or a mastectomy.
Reoperation rate is not an NCDB data field. A reoperation
can be identified by the fields of ‘‘first surgical procedure,
days from diagnosis’’ and ‘‘definitive surgical procedure,
days from diagnosis.’’ If the latter is greater than the for-
mer, then a reoperation occurred.2 Patients with 0 days
between first and definitive procedures were excluded from
the study. Thus, patients with excisional biopsy for first
surgery and patients with needle biopsy and definitive
surgery on the same day also were excluded.
Independent Variables
The primary predictor variable was receipt of NAC,
determined by comparing days to initial surgery and days
to initial chemotherapy. The ROR for the patients with
receipt of NAC was compared with that for the patients
receiving postoperative chemotherapy. A secondary pre-
dictor variable was breast cancer subtype. Because
information on breast cancer subtypes based on multigene
signature testing is limited to a small proportion of all
breast cancer patients in the NCDB, we used the St. Gallen
immunohistochemistry (IHC) surrogate subtypes9–15
(Fig. 1). Patients with a borderline values for estrogen
receptor (ER), progesterone receptor (PR), or human
epidermal growth factor 2 (HER2) were excluded from the
study.
In the multivariable modeling, the independent variables
included patient, facility, and tumor variables previously
used by NCDB investigators for ROR, as well as those
used in investigations from other databases.1–4,16 These
variables included patient age, race, insurance status,
comorbidities (Charlson/Deyo Score), education, income,
tumor size, node status, and facility type, location, and
volume. When a single facility type was coded as more
than one type or unknown, we created ‘‘multiple’’ and
‘‘unknown’’ categories. When phenotypic IHC cancer
subtypes were used as a predictor variable, then hormone
receptor status, HER2 status, and tumor grade were
excluded as covariates in the regression models.
Statistical Analysis
The Cochrane Armitage test was used to determine
trends in ROR from 2010 to 2013. A univariate (unad-
justed) computation of NAC, breast cancer subtypes, and
all covariates with ROR was performed using v2 tests.
Multiple multivariable logistic regression analyses were
performed to characterize the association between receipt
of NAC, cancer subtypes, and ROR, with adjustment for all
the confounding variables. For all tests, p values lower than
0.05 were considered significant. The models were first run
for all patients older than 18 years, then repeated for
patients older than 70 years.
A second set of models, including all patients receiving
chemotherapy, comprised matched cases (those receiving
NAC) and control subjects (those not receiving NAC)
according to propensity scores. The propensity scores were
estimated probabilities of patients receiving NAC based on
patient age and tumor characteristics (size, nodal status,
and clinical stage). A boundary was set requiring that the
propensity score of two patients (one receiving NAC and
one not receiving NAC) must differ by less than 0.10 when
cases and control subjects were matched. A logistic model
with matched pairs then was used to model the likelihood
of reoperation based on NAC, with adjustment for con-
founding variables related to patient and facility
characteristics. The CONSORT diagram for the models is
seen in Fig. 1.
Next, models were developed to determine whether an
association existed between breast cancer subtypes and
ROR in a patient cohort receiving NAC. After identifica-
tion of a significant association, a model was developed to
determine whether the association between subtypes and
ROR persisted when the cohort was restricted to include
only the patients with a pathologic complete response
(pCR) to NAC. All statistical analyses were performed
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FIG. 1 CONSORT diagram
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with SAS software, version 9.3 (SAS Institute Inc., Cary
NC, USA).
RESULTS
The primary analysis comprised 71,627 initial lumpec-
tomy patients. All received chemotherapy either pre- or
postoperatively. Overall, the mean and median (range) of
elapsed days from diagnosis to first surgical procedure
were respectively 53 and 30 days (range 1–1241 days). In
the reoperation group, these periods were respectively 23
and 21 days (range 1–60 days). After exclusion of cases
with missing values for these fields, the number of days
from diagnosis to first surgical procedure and to definitive
surgical procedure were equal among all the patients who
did not undergo reoperation. The mastectomy rate was
4.2% (510/12,157) in the NAC group and 7.6% (4521/
59,470) in postoperative adjuvant group (p\ 0.001).
The patients with and without receipt of NAC were
compared. The proportion of patients receiving NAC was
17%, increasing from 15.6% in 2010 to 17.9% in 2013 (p\
0.001). Concurrently, the ROR for all the patients in this
group was 18.8%, decreasing from 20.4% in 2010 to 17.4%
in 2013 (p \ 0.001) (Fig. 2). Of all reoperations, 8413
(62.6%) were the lumpectomy type and 5031 (37.4%) were
the mastectomy type.
A significant association was observed between the use
of NAC, breast cancer subtypes, and ROR when control
was used for all the confounding variables (Table 1;
Figs. 2, 3). The odds of reoperation were reduced with
receipt of NAC in all models except for stage 1 patients
with a luminal A subtype. The rates were higher for
younger patients with larger tumors and invasive lobular
histology. The association between NAC and fewer reop-
erations was strongest for the patients with the higher
breast cancer stage, HER2 overexpression, and triple-neg-
ative (TN) cancers. The patients with triple-negative
cancers and HER2 overexpression receiving NAC had the
lowest ROR (6.4 and 7.3%, respectively). The overall study
results did not change in models restricted to patients older
than 70 years (data available upon request).
After propensity score matching, each of the matched
comparison groups had 8056 patients, including those who
received NAC versus those who received chemotherapy
after surgery. In these models, the associations between
NAC, subtypes and ROR persisted (Table 1; Fig. 3).
In the assessment of tumor response to NAC, the results
were unknown for a notable fraction of cases (59% of
luminal A, 52% of luminal B1, 49% of luminal B2, 46% of
triple-negative, and 42% of HER2 cases). For the cases
with known results, the pCR rates after NAC were 17% for
the luminal A type, 35.9% for the B1 type, 48.1% for the
B2 type, 50.7% for the triple-negative type, and 62.8% for
the HER2 type patients. For the patients with a pCR to
NAC, the overall ROR for all the subtypes was 4.1%. For
the models restricted to the patients not receiving NAC and
a separate model including only the patients with a pCR to
NAC, the association between subtype and ROR persisted,
indicating an intrinsic association between subtype and
ROR not dependent on tumor responsiveness to NAC
(Table 2; Fig. 3).
DISCUSSION
Too many reoperations occur after initial lumpectomy
for breast cancer. In the decade ending 2013, nearly one in
three women who underwent lumpectomy in the state of
New York required a reoperation.17 In the United States
and Britain, the reoperation rates average 20–25%.1–4
Rates higher than 50% have been reported, yet some cen-
ters report rates lower than 10%, proving that low rates are
achievable.1–3,18,19 The majority of surgeons participating
in a national consensus conference recommended a 10%
reoperation rate as a target benchmark.5
Our study aimed to assess the association between NAC,
breast cancer subtypes, and lumpectomy reoperation rates
in a population-based database, including patients who
received chemotherapy either before or after surgery, to
identify opportunities to lower rates. After adjustment for
all covariates known to influence the ROR, we identified a
strong association between the receipt of NAC and
reductions in reoperations for patients undergoing initial
lumpectomy for clinical stages 1–3 breast cancer. Overall,
the relative odds of reduction in ROR with chemotherapy
before rather than after surgery was 47%. The level of


















FIG. 2 Trends for reoperation rates and receipt of neoadjuvant
chemotherapy. ROR reoperation rates after lumpectomy for invasive
breast cancer, NAC receipt of neoadjuvant chemotherapy, NAC rate
proportion of Stages 1–3 breast cancer patients receiving NAC
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benefit increased with cancer stage. The relative odds of
reduction were 35% for stage 1, 50% for stage 2, and 73%
for stage 3 patients. The greatest benefit of decreased ROR
was seen for patients with the subtypes known to have the
highest response rates to chemotherapy (HER2, and TN).
For these patients, the relative odds of a reduction in ROR
with NAC were respectively 66 and 53% compared to 13
and 36% for the luminal A and B1 types. The unadjusted
ROR for the patients with the TN and HER2 subtypes
receiving NAC was very low (6.4 and 7.3%, respectively).
Receipt of NAC was associated with fewer reoperations
for all age groups, including those patients older than
70 years, a subgroup seldom enrolled in the clinical efficacy
trials. The only patient subgroup of any age with no associ-
ation between NAC and ROR was that including patients
who had stage 1 cancer with a luminal A subtype, a cohort not
TABLE 1 Association of receipt of neoadjuvant chemotherapy, cancer stage, and breast cancer subtypes with reoperation rates
Patient cohort Unadjusted ROR ROR (%) OR 95% CI p value
N D % Without NAC With NAC Lower Upper
Stages 1–3
Stages 1–3 13444 71627 18.8 20.3 11.4 0.53 0.49 0.57 \0.001
Stage 1 7344 40655 18.1 18.4 13.0 0.65 0.56 0.75 \0.001
Stage 2 5728 28985 19.8 23.1 11.0 0.50 0.45 0.56 \0.001
Stage 3 372 1987 18.7 46.0 11.0 0.27 0.19 0.38 \0.001
Stages 1–3 by type
Luminal A 5272 22787 23.1 23.6 20.0 0.84 0.76 0.93 0.001
Luminal B1 2701 14066 19.2 20.3 12.8 0.64 0.56 0.74 \0.001
Luminal B2 2413 12416 19.4 21.4 10.6 0.49 0.42 0.57 \0.001
Triple-negative 2177 17617 12.4 14.0 6.4 0.47 0.41 0.55 \0.001
HER2 overexpressed 881 4741 18.6 22.7 7.3 0.34 0.27 0.43 \0.001
Stages 1–3 by type with PSM
Luminal A 1187 4816 24.6 27.8 21.3 0.74 0.62 0.89 0.002
Luminal B1 662 3170 20.9 25.2 15.5 0.56 0.43 0.73 \0.001
Luminal B2 497 2805 17.7 22.7 13.0 0.49 0.37 0.65 \0.001
Triple-negative 490 4209 11.6 15.6 8.3 0.46 0.36 0.59 \0.001
HER2 overexpressed 211 1112 19.0 19.0 10.7 0.31 0.19 0.50 \0.001
Stage 1 by type
Luminal A 2828 13891 29.5 20.5 17.8 0.92 0.75 1.12 0.381
Luminal B1 1276 7113 17.9 18.2 13.0 0.73 0.53 0.99 0.044
Luminal B2 1539 7620 20.2 20.7 13.7 0.65 0.50 0.83 \0.001
Triple-negative 1198 9572 12.5 12.9 8.2 0.61 0.46 0.81 \0.001
HER2 overexpressed 503 2459 20.5 21.4 10.2 0.43 0.27 0.70 \0.001
Stage 2 by type
Luminal A 2307 8453 27.3 28.8 21.1 0.76 0.67 0.87 \0.001
Luminal B1 1323 6509 20.3 22.5 12.4 0.61 0.51 0.73 \0.001
Luminal B2 818 4494 18.2 22.6 9.3 0.46 0.37 0.56 \0.001
Triple-negative 929 7493 12.4 15.6 6.3 0.47 0.39 0.57 \0.001
HER2 overexpressed 351 2036 17.2 25.0 6.6 0.32 0.23 0.44 \0.001
Stage 3 by type
Luminal A 137 443 30.9 52.0 19.7 0.34 0.21 0.55 \0.001
Luminal B1 102 444 23.0 45.5 14.6 0.37 0.22 0.64 \0.001
Luminal B2 56 302 18.5 51.0 12.0 0.23 0.11 0.49 \0.001
Triple-negative 50 552 9.1 35.7 4.3 0.14 0.07 0.28 \0.001
HER2 overexpressed 27 246 11.0 37.9 7.4 0.35 0.13 0.96 0.041
ROR reoperation rates after lumpectomy for invasive breast cancer, OR odds ratio, CI confidence interval, N numerator, D denominator; NAC,
receipt of neoadjuvant chemotherapy, HER2 human epidermal growth factor receptor 2, PSM propensity score matching
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often recommended for chemotherapy according to the
National Comprehensive Cancer Network Guidelines except
when identified as having a higher risk of cancer recurrence,
as measured by the 21-gene multigene signature testing.
Seeking to determine whether the association of cancer
subtype with ROR was solely due to its differential rates of
response to NAC or whether there could be a distinct
independent association of cancer subtype with ROR, we
separately calculated ROR by subtype for a cohort of
patients who had a pCR to NAC and, using a separate
model, for the patients who did not receive any NAC. In
both models, an association between subtypes and ROR
persisted. This supports the notion that subtypes have an
intrinsic association with reoperations, another example of
the biologic heterogeneity of breast cancer. Because no
reoperations would be expected for positive margins in
patients having a complete response to NAC, the few
reoperations (4%) that did occur in this cohort were likely
due to wound complications, bleeding, or other causes not
related to margin status.
Reoperation odds Ratio
Comparing  NAC  to  no  NAC
( reference   level  no NAC)
1   Stage  1  to  3
2   Stage  1  
3   Stage  2  
4   Stage  3 
5    Luminal   A:  NAC yes  vs  no
6    Luminal   B1:  NAC yes  vs  no
7    Luminal   B2:  NAC yes  vs  no
8    Triple   Neg:  NA  yes  vs   no
9    Her  2  type:   NAC yes vs   no
10    Luminal   A:  NAC yes   vs  no
15    Luminal   B1: vs  Luminal   A
19    Luminal   B1: vs  Luminal   A
16    Luminal   B2: vs  Luminal   A
20    Luminal   B2: vs  Luminal   A
17    Triple     Neg: vs  Luminal   A
21    Triple     Neg: vs  Luminal   A
26    NOS vs < 2 cm
27    2-5 cm vs <2 cm
28    >5 cm vs <2 cm
29    Negative vs positive
30    40  to  49  vs  less  than  40
31    50  to  59  vs  less  than  40
32    60  to  69  vs  less  than  40
33    70  to  79  vs  less  than  40
34    80  or  greater  vs  less  than  40
22    HER  2  Type: vs  Luminal   A
23    Invasive  lobular     vs   inv   ductal
24    Invasive  other    vs   inv   ductal
25    Invasive  mixed/plus   vs   inv   ductal
18    Her  2  Type:  vs  Luminal   A
11    Luminal   B1:   NAC yes vs   no
12    Luminal   B2:   NAC yes vs   no
13    Triple     Neg:   NAC yes  vs  no
14    Her 2    type:    NAC yes  vs  no
Comparing  NAC  to  no  NAC within subtype
( reference  level  no NAC, subtype fixed)
Comparing  NAC  to  no  NAC within subtype (PSM)
( reference  level  no NAC, matched data)
Comparing  ROR among subtype with pCR
( reference  level  Luminal A, NAC with pCR)
Comparing  ROR among subtype with  no NAC
( reference  level  Luminal A, no NAC)
Histologic subtype*
( reference  level  invasive ductal)
Tumor size
( reference  level  < 2 cm)
Node status
( reference  level  positive)
Age group
( reference  level   <  40 years)
0.50.1
Odds ratio with 95% confidence interval
1.5 2.5 3.5 4.51 2 3
FIG. 3 Forest plot of associations between neoadjuvant chemother-
apy receipt and lumpectomy reoperation rates in Stages 1–3 breast
cancer. Asterisk Histologic categories: Invasive ductal, invasive
lobular, invasive ‘‘mixed/plus’’ (invasive ductal plus other invasive
type and/or DCIS; excludes LCIS), invasive other (all others not
previously specified). NAC receipt of neoadjuvant chemotherapy,
PSM propensity score matching, pCR pathologic complete response
to neoadjuvant chemotherapy
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Future research into the reason why cancer subtypes may
have an independent association with a surgical outcome
such as ROR is warranted. Although further investigation is
warranted, one reason may be a possible relationship
between subtype and tumor focality. If some subtypes are
more often multifocal or multicentric, then the likelihood of
positive margins necessitating re-excision would be expec-
ted to increase. In support of this hypothesis, Pekar et al.,20
using large-format histologic techniques, reported that
patients with triple-negative tumors had the lowest chance of
multifocal or diffuse disease, and those with HER2 subtypes
had the highest chance. This result correlates with our find-
ings that for patients not receiving NAC, the triple-negative
patients had the lowest ROR (14%), and the HER2 patients
had a higher ROR (23%).
The use of NAC is increasing, and evidence shows its
effectiveness in increasing breast-conserving therapy
rates.6 Few studies have reported the effect of NAC on
breast reoperations.21–24 Single-institution reports from
Turkey and the University of Michigan associated NAC
with a modest reduction in lumpectomy ROR.22,23 In
contrast, Al-Hilli et al.21 found no change in ROR for
patients undergoing mastectomy captured from the NSQIP
database, and Volders et al.24 reported higher ROR after
NAC for patients undergoing breast-conserving therapy in
the Dutch Pathology Registry. The methods of the Dutch
study differed from the methods of the current study. In the
only prior study of ROR using the NCDB, patients
receiving NAC were excluded.2
Our study findings are applicable to breast cancer patients
either wanting or considering lumpectomy who are other-
wise eligible for chemotherapy. Our study was not designed
to address the issue of whether a patient should receive
chemotherapy. Rather, we aimed to address whether the
timing of chemotherapy was associated with reoperation
rates in a cohort of patients receiving chemotherapy.
The strengths of this study included the large sample
size of the NCDB and its demographic diversity, increasing
its generalizability. The concept of discussing chemother-
apy sequencing during shared decision making with the
patient as a method to lower reoperations should not con-
tribute to the unintended consequences that have been
attributed to other initiatives aimed at lowering ROR, such
as larger lumpectomies, worse cosmetic outcomes, and
increased mastectomy rates from surgeon risk aversion, a
fear of being penalized for a reoperation if the surgeon is
participating in a quality improvement program.25 It could
even be postulated that better cosmetic outcomes might
result from smaller lumpectomies for patients demonstrat-
ing a good clinical response to NAC. For these patients,
surgeons do not necessarily need to resect the entire extent
of tumor based on its size estimate before NAC, a practice
endorsed by the 2015 St. Gallen panel.9
This study had limitations. The NCDB is not intended to
be a surgical outcomes registry. For example, the NCDB
does not have a data field for ROR. It is captured by dates
of service for first surgery and definitive surgery. In addi-
tion, the NCDB has missing data for some of its fields,
including those most notable in this study for assessing
tumor response to NAC. These results were missing for
about half the cases.
Another limitation was that the NCDB does not record
the reported reasons for reoperation described by oth-
ers.1,3,5,16 Our results might differ if any of these
confounding variables were unequally distributed between
our patients receiving or not receiving NAC. In addition, in
this nonrandomized retrospective review, selection bias for
the initial decision to counsel a patient to undergo NAC
TABLE 2 Demonstration of association between breast cancer subtype and reoperation rate independent of the effect of neoadjuvant
chemotherapy
ROR (%) OR 95% CI p Value Overall p Value
Patient cohort Subtype Luminal A Lower Upper
No NAC (stages 1–3)
Triple-negative vs luminal A 14.0 24.0 0.69 0.65 0.73 \0.001 \0.001
HER2 overexpressed vs luminal A 22.7 24.0 1.27 1.16 1.38 \0.001
Luminal B1 vs luminal A 20.3 24.0 0.94 0.88 0.99 0.028
Luminal B2 vs luminal A 21.4 24.0 1.11 1.05 1.18 0.001
NAC and complete pathologic response (stages 1–3)
Triple-negative vs luminal A 2.6 15.5 0.25 0.13 0.47 \0.001 \0.001
HER2 overexpressed vs luminal A 3.1 15.5 0.36 0.17 0.76 0.001
Luminal B1 vs luminal A 4.2 15.5 0.40 0.19 0.83 0.015
Luminal B2 vs luminal A 3.8 15.5 0.35 0.18 0.69 0.002
ROR reoperation rates after lumpectomy for invasive cancer, OR odds ratio, CI confidence interval, NAC receipt of neoadjuvant chemotherapy,
HER2 human epidermal growth factor receptor 2
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versus surgery and to undergo mastectomy versus
lumpectomy after NAC could occur. For example, if the
same patient and tumor factors predicting a tumor response
to NAC that achieves the goal of breast preservation are
similar to those associated with lower ROR, and the
patients with poor responses to NAC were sent to the initial
mastectomy group, excluding them from our study, then
the benefit of NAC lowering ROR in the initial lumpec-
tomy group may be exaggerated. Our secondary analyses
attempted to account for the differences in biology (IHC
phenotypic subtypes) and patient/tumor characteristics
(propensity score matching) that were part of the clinical
decision to recommend NAC, but they were insufficient to
rule out selection bias.
Finally, in the NCDB and other national databases, some
data fields may be misclassified. Investigators cannot
determine how often this occurs. It also can be difficult to
confirm a cause-and-effect relationship even when strong
statistical associations are identified.6
CONCLUSION
The administration of chemotherapy before instead of
after surgery is associated with a highly significant reduc-
tion in reoperations after the initial lumpectomy for breast
cancer. Benefits are identified with all cancer subtypes but
are greatest for patients with cancers classified as TN,
HER2, or higher stage disease. A decreased re-excision
rate after neoadjuvant chemotherapy represents another
advantage to this approach and should be included for an
informed discussion of risk and benefits.
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